COMPARISON OF ONCE-DAILY INTRAVENOUS AND ORAL OMEPRAZOLE ON PENTAGASTRIN-STIMULATED ACID-SECRETION IN DUODENAL-ULCER PATIENTS

被引:13
作者
CEDERBERG, C [1 ]
LIND, T [1 ]
ROHSS, K [1 ]
OLBE, L [1 ]
机构
[1] SAHLGRENS UNIV HOSP,DEPT SURG,S-41345 GOTHENBURG,SWEDEN
关键词
ACID SECRETION; PENTAGASTRIN; DUODENAL ULCER PATIENTS; OMEPRAZOLE; INTRAVENOUS ADMINISTRATION; ORAL ADMINISTRATION; MULTIPLE DOSES; PHARMACOKINETICS;
D O I
10.1159/000200992
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The effect of 5 days of once-daily dosing with 20 mg p.o. and 40 mg i.v. omeprazole on pentagastrin-stimulated acid secretion was studied in 8 patients with duodenal ulcer. In addition they also received a 10-mg i.v. dose on day 6 during the oral treatment period. The antisecretory effect was measured 6-7 h after dose at a time point when maximal inhibition during the dosing interval is anticipated. The median percent inhibition of peak acid output (PAO) markedly increased from 43% on day 1 to 100% on day 5 during treatment with 20 mg p.o. The first 40-mg i.v. dose produced a median inhibition of 98% of PAO already on day 1. After 5 days of dosing, the inhibition had increased to 100%. On the other hand, a 10-mg i.v. dose could essentially maintain the degree of PAO reduction reached after 5 days of oral treatment. Plasma omeprazole concentrations increased during repeated dosing both with 20 mg p.o. and 40 mg i.v.
引用
收藏
页码:171 / 178
页数:8
相关论文
共 22 条
[11]  
LIND T, 1986, SCAND J GASTROE S118, V20, P137
[12]   THE MECHANISM FOR INHIBITION OF GASTRIC (H++K+)-ATPASE BY OMEPRAZOLE [J].
LORENTZON, P ;
EKLUNDH, B ;
BRANDSTROM, A ;
WALLMARK, B .
BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 817 (01) :25-32
[13]   INHIBITION OF (H++K+)-ATPASE BY OMEPRAZOLE IN ISOLATED GASTRIC VESICLES REQUIRES PROTON TRANSPORT [J].
LORENTZON, P ;
JACKSON, R ;
WALLMARK, B ;
SACHS, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 897 (01) :41-51
[14]  
MEYRICK-THOMAS J, 1984, British Medical Journal, V289, P525
[15]  
MULLER P, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1685
[16]   THE RATE OF HEALING OF DUODENAL-ULCERS DURING OMEPRAZOLE TREATMENT [J].
NAESDAL, J ;
LIND, T ;
BERGSAKERASPOY, J ;
BERNKLEV, T ;
FARUP, PG ;
GILLBERG, R ;
HALVORSEN, L ;
KILANDER, A ;
OFFERGAARD, S ;
WALAN, A ;
LLOYDDAVIES, KA .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 (06) :691-695
[17]   EFFECT OF OMEPRAZOLE, A SUBSTITUTED BENZIMIDAZOLE, ON 24-H INTRAGASTRIC ACIDITY IN PATIENTS WITH PEPTIC-ULCER DISEASE [J].
NAESDAL, J ;
BODEMAR, G ;
WALAN, A .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1984, 19 (07) :916-922
[18]   DEVELOPMENT OF AN ORAL FORMULATION OF OMEPRAZOLE [J].
PILBRANT, A ;
CEDERBERG, C .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 :113-120
[19]   CLONING AND EXPRESSION OF COMPLEMENTARY DNAS FOR MULTIPLE MEMBERS OF THE HUMAN CYTOCHROME-P450IIC SUBFAMILY [J].
ROMKES, M ;
FALETTO, MB ;
BLAISDELL, JA ;
RAUCY, JL ;
GOLDSTEIN, JA .
BIOCHEMISTRY, 1991, 30 (13) :3247-3255
[20]  
Walan A., 1989, GASTROENT HEPAT-BARC, V4, P27